Endpoints News 3 mars 2026 After years of dispute with FDA, Vanda will get a public hearing for jet lag drug
Endpoints News 3 mars 2026 FDA explains how some copycat drugs can still win three years of exclusivity
Endpoints News 3 mars 2026 EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
Endpoints News 3 mars 2026 Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Endpoints News 3 mars 2026 Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
Endpoints News 2 mars 2026 United Therapeutics to take pulmonary hypertension drug to FDA for approval
Endpoints News 2 mars 2026 Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Endpoints News 2 mars 2026 Roche gets third pivotal win with MS drug, but liver signal could be a problem